{"id":72156,"date":"2026-08-10T12:50:10","date_gmt":"2026-08-10T04:50:10","guid":{"rendered":"https:\/\/flcube.com\/?p=72156"},"modified":"2026-08-10T12:50:12","modified_gmt":"2026-08-10T04:50:12","slug":"salubriss-sal0195-sirna-drug-wins-nmpa-nod-for-lpa-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72156","title":{"rendered":"Salubris&#8217;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Salubris<\/strong> Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002294:SHE\">SHE:\u202f002294<\/a>) announced that its self\u2011developed innovative <strong>siRNA drug SAL0195<\/strong> has been approved by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> to conduct <strong>clinical trials<\/strong> for the treatment of <strong>elevated lipoprotein(a) [Lp(a)]<\/strong>. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Salubris (SHE:\u202f002294)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SAL0195<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>siRNA (small interfering RNA) drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Elevated lipoprotein(a) [Lp(a)]<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>08\u202fAug\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Self\u2011developed innovative <strong>siRNA<\/strong> (small interfering RNA) therapeutic<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Lipoprotein(a)<\/strong> [Lp(a)] \u2014 an independent, genetically determined cardiovascular risk factor<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Highly potent and specific <strong>RNA interference (RNAi)<\/strong> that selectively knocks down hepatic expression of Lp(a), reducing circulating levels<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Investigational siRNA drug<\/li>\n\n\n\n<li><strong>Differentiator:<\/strong> Long\u2011acting target knockdown effect demonstrated in preclinical models<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>SAL0195 Result<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Knockdown Duration<\/strong><\/td><td><strong>Up to 140 days<\/strong> following a single dose<\/td><td>Potential for <strong>quarterly or less frequent dosing<\/strong><\/td><\/tr><tr><td><strong>Species Model<\/strong><\/td><td>Non\u2011human primate (monkey)<\/td><td>Translationally relevant for human pharmacodynamics<\/td><\/tr><tr><td><strong>Potency<\/strong><\/td><td>Highly potent and specific<\/td><td>Supports competitive positioning vs. other Lp(a)\u2011targeting agents<\/td><\/tr><tr><td><strong>Safety (Preclinical)<\/strong><\/td><td>Generally well tolerated<\/td><td>Supports progression to human trials<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">In preclinical monkey models, SAL0195 demonstrated a <strong>long\u2011acting target knockdown effect lasting up to 140 days<\/strong> following a single dose, a pharmacodynamic profile that suggests the potential for infrequent dosing intervals in humans \u2014 a meaningful advantage in the lipid\u2011lowering space where adherence is a persistent challenge.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lp(a) Landscape:<\/strong> Elevated Lp(a) affects roughly <strong>1 in 5 people globally<\/strong> and is an independent risk factor for atherosclerotic cardiovascular disease, yet no approved therapies specifically target Lp(a) reduction. The market opportunity for a first\u2011in\u2011class or best\u2011in\u2011class Lp(a)\u2011lowering agent is substantial.<\/li>\n\n\n\n<li><strong>siRNA Competitive Dynamics:<\/strong> <strong>Novartis&#8217;s pelacarsen<\/strong> (antisense oligonucleotide) and <strong>Amgen&#8217;s olpasiran<\/strong> (siRNA) are the most advanced Lp(a)\u2011targeting candidates globally, both in Phase\u202f3. SAL0195 enters the race with a <strong>preclinical knockdown duration<\/strong> that rivals or exceeds reported profiles of competitors, potentially supporting a differentiated dosing regimen.<\/li>\n\n\n\n<li><strong>Salubris Pipeline Inflection:<\/strong> SAL0195 represents Salubris\u2019s entry into the <strong>RNA therapeutics<\/strong> space, a strategic pivot beyond its established cardiovascular small\u2011molecule franchise. The NMPA green light triggers a <strong>Phase\u202f1<\/strong> dosing program in China, with potential for global expansion.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project the global Lp(a)\u2011targeted therapy market could reach <strong>$5\u20138\u202fbillion<\/strong> annually by the early 2030s if cardiovascular outcome trials demonstrate event reduction. A domestically developed siRNA with quarterly dosing could capture meaningful share in China and emerging markets.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Salubris is expected to initiate <strong>Phase\u202f1<\/strong> first\u2011in\u2011human studies in China in late 2026 or early 2027, with initial pharmacodynamic readouts anticipated in H2\u202f2027.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development, regulatory timeline, and commercial potential of SAL0195. Actual results may differ materially due to risks including clinical trial outcomes, manufacturing scale\u2011up, regulatory requirements, competitive dynamics, and market acceptance. The NMPA clinical trial approval does not guarantee marketing authorization. Investors should consult official filings for updated risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8eSAL0195\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8eSAL0195\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-a3094a2d-d1bb-4a06-a953-29ea4b39c537\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8eSAL0195\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8eSAL0195\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8eSAL0195\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a3094a2d-d1bb-4a06-a953-29ea4b39c537\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,69,64,335,1167],"class_list":["post-72156","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cvd","tag-rnai-aso","tag-salubris-pharmaceuticals","tag-she-002294"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Salubris&#039;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72156\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salubris&#039;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72156\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T04:50:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T04:50:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72156#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72156\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Salubris&#8217;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials\",\"datePublished\":\"2026-08-10T04:50:10+00:00\",\"dateModified\":\"2026-08-10T04:50:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72156\"},\"wordCount\":537,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CVD\",\"RNAi \\\/ ASO\",\"Salubris Pharmaceuticals\",\"SHE: 002294\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72156#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72156\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72156\",\"name\":\"Salubris's SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T04:50:10+00:00\",\"dateModified\":\"2026-08-10T04:50:12+00:00\",\"description\":\"Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72156#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72156\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72156#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salubris&#8217;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Salubris's SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72156","og_locale":"en_US","og_type":"article","og_title":"Salubris's SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials","og_description":"Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.","og_url":"https:\/\/flcube.com\/?p=72156","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T04:50:10+00:00","article_modified_time":"2026-08-10T04:50:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72156#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72156"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Salubris&#8217;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials","datePublished":"2026-08-10T04:50:10+00:00","dateModified":"2026-08-10T04:50:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72156"},"wordCount":537,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CVD","RNAi \/ ASO","Salubris Pharmaceuticals","SHE: 002294"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72156#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72156","url":"https:\/\/flcube.com\/?p=72156","name":"Salubris's SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T04:50:10+00:00","dateModified":"2026-08-10T04:50:12+00:00","description":"Salubris Pharmaceuticals (SHE:\u202f002294) announced that its self\u2011developed innovative siRNA drug SAL0195 has been approved by China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid\u2011lowering pathways.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72156#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72156"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72156#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Salubris&#8217;s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72156"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72156\/revisions"}],"predecessor-version":[{"id":72160,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72156\/revisions\/72160"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}